Dr. Andrew Hoffman is a Professor of Large Animal Internal Medicine with three decades of experience teaching, clinical service, and research. Dr. Hoffman’s major areas of expertise include pulmonary physiology, tissue engineering, and stem cell-based therapies. Dr. Hoffman developed the first outpatient pulmonary function testing unit for veterinary patients in North America which currently operates in the Hospital for Large Animals. He directs the Regenerative Medicine Laboratory (RML) that serves as a research and laboratory core for Clinical Science faculty engaged in research related to stem cells and regenerative medicine. Dr. Hoffman’s laboratory has continuously received funding from the National Institute of Health (NIH) since 1999, in addition to numerous industry and foundation awards.
At present, the main focus of Dr. Hoffman’s clinical research is mesenchymal stem cell (MSC) safety, potency, and biological activity, in veterinary and by extension human patients with a variety of persistent diseases. Mechanisms by which MSCs convey immunoregulatory and anti-inflammatory signals to recipient cells that are under investigation include, the release of soluble mediators and extracellular vesicles (nanoparticles). In addition to these more basic science questions, the RML directed by Dr. Hoffman facilitates clinical trials in veterinary patients, including the training and supervision of clinical trial technicians and coordinators, laboratory support including measurement of biomarkers and cells (flow cytometry), study design, quality control, and biostatistics. Examples of veterinary clinical trials facilitated by the RML include the effects of MSCs on autoimmune disease (perianal fistulas, granulomatous meningoencephalomyelitis, immune complex glomerulonephritis, and hepatitis), sepsis, osteoarthritis, and inter-vertebral disc disease progression in dogs. Additionally Dr. Hoffman is currently a Principal Investigator on a translational project funded by NIH entitled ‘Autologous mesenchymal stem cell therapy for emphysema’ (R01 HL112987-01A1) which aims to understand how stem cells enhanced by biological scaffolds can activate the repair of the emphysema lung.
The RML also offers Post-Doctoral training opportunities for veterinarians who have completed their Veterinary Residency programs, which are supported by NIH and Foundation funding. Finally, the RML is responsible for maintaining the animal stem cell bank, comprised of a variety of stem cell lines from veterinary patients with naturally occurring diseases for studies of disease mechanisms, and cell lines from normal animals (dogs, cats, horses) intended for use in clinical trials.. Dr. Andrew Hoffman received an Exceptional Service Award at Tufts University Cummings School of Veterinary Medicine in 2013 for activities as Director of the RML. He resides with his family in Sutton, MA.